If you look at all the three deals Novartis made in the HCV space with Idenix,Anadys and HGSI as an outsider, I felt the deals were lousy. Thats my opinion and is not an analysis :-)
I thought you said the Vertex deal wasn't so good in the morning. What made you change your mind?
Market Data 
Markets 
AI
